Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials — Jarem Edwards (2019) | RDL Network
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Article 2019 en
Authors
JE
Jarem Edwards
AT
Annie Tasker
IS
Inês Pires da Silva
Abstract
1 min read
This study provides the first comprehensive assessment of immune checkpoint receptor expression in any cancer and provides important data for rational selection of targets for trials and predictive biomarker development.
Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela L. Ferguson, Ruth Allen, Benjamin Allanson, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A Scolyer
Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela L. Ferguson, Ruth Allen, Benjamin Allanson, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A Scolyer
Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela L. Ferguson, Ruth Allen, Benjamin Allanson, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A Scolyer
Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela L. Ferguson, Ruth Allen, Benjamin Allanson, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A Scolyer
Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela L. Ferguson, Ruth Allen, Benjamin Allanson, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A Scolyer
Discussion(0)
No comments yet. Be the first to comment.